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In spite of the development of new anticancer drugs by the pharmaceutical industry, melanoma and T
lymphomas are diseases for which medical advances remain limited. Thus, there was an urgent need of
new therapeutics with an original mechanism of action. Since several years, our group develops quinox-
alinic compounds. In this paper, the ﬁrst preclinical results concerning one lead compound, EAPB0203,
are presented. This compound exhibits in vitro cytotoxic activity on A375 and M4Be human melanoma
cell lines superior to that of imiquimod and fotemustine. A liquid chromatography–mass spectrometry
method was ﬁrst validated to simultaneously quantify EAPB0203 and its metabolite, EAPB0202, in ratmidazo[1,2-a]quinoxaline
C/ESI–MS
elanoma
n vitro and in vivo cytotoxic activities
harmacokinetics
ub-acute toxicity
plasma. Thereafter, the pharmacokinetic proﬁles of EAPB0203 were studied in rat after intravenous and
intraperitoneal administrations. After intraperitoneal administration the absolute bioavailability remains
limited (22.7%). In xenografted mouse, after intraperitoneal administration of 5 and 20mg/kg, EAPB0203
ismore potent than fotemustine. The survival timewas increasedup to 4 and2weeks compared to control
mice andmice treated by fotemustine, respectively. The results of this study demonstrate the relationship
between the dose of EAPB0203 and its effects on tumor growth. Thus, promising efﬁcacy, tolerance and
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. Introduction
Melanoma is an increasingly common, potentially fatal form
f skin cancer arising from the malignant transformation of
elanocytes. Responsible of several thousand deaths each year,
elanoma is the most frequent malignant tumor in the white
uman population worldwide (Greinert, 2009). Its frequency
ncreases dramatically with age and chronic sun exposure. Only
few chemotherapeutic agents that are active in ﬁghting cancer
ells have been shown to be active in the treatment of melanomas,
ither one at a time or in combinations. Imidazoquinoline com-Please cite this article in press as: Khier, S., et al., Pharmacology of EAPB02
activity on melanoma. Eur. J. Pharm. Sci. (2009), doi:10.1016/j.ejps.2009.10
ounds have potent antiviral and antitumor properties in animals,
nd have been clinically approved for the topical treatment of
enital and anal warts (Hengge and Cusini, 2003; Sauder, 2003).
miquimod, the ﬁrst member of the imidazoquinolone family is
∗ Corresponding author. Tel.: +33 4 67 54 80 75; fax: +33 4 67 54 80 75.
E-mail address: FBressolle@aol.com (F.M.M. Bressolle).
1 Both these authors contributed equally to this work.
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fﬁcacious as a topical therapy for certain types of skin cancers:
asal cell carcinoma, Bowen’s disease, superﬁcial squamous cell
arcinoma, some superﬁcialmalignantmelanomas and actinic ker-
tosis (Steinmann et al., 2000; van Egmond et al., 2007). Extensive
tudies over the past years have indicated that imiquimod acts
oth: (i) indirectly, by activating the innate as well as the adap-
ive immune system via binding to cell surface receptors such as
oll-like receptors (TLR) 7 and 8, thereby inducing the activation
f transcription factors like nuclear factor NF-B and resulting in
he secretion of pro-inﬂammatory cytokines predominantly inter-
eron (IFN)-, tumornecrosis factor (TNF)- and interleukin (IL)-12
Hemmi et al., 2002; Hengge and Cusini, 2003; Rudy, 2002; Sauder,
003); and (ii) directly, by inducing direct in vitro and in vivo
ro-apoptotic activities in a rather tumor selective manner, requir-
ng the activation of the ‘work horses’ of apoptosis, the caspases’03, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral
.006
amily of proteases (Schön et al., 2003, 2004). Imiquimod inhibits
elanogenesis and proliferation of human melanocytes (Kang et
l., 2009). Recently, its therapeutic spectrum was extended to
utaneous B-cell lymphomas (Spaner et al., 2005). Resiquimod,
nalog of imiquimod, has greater potency at inducing cytokine
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two analytes were added in order to obtain calibration curves inARTICLEModelHASCI-1959; No.of Pages7
S. Khier et al. / European Journal of Ph
xpression. Unfortunately, imiquimod and particularly resiquimod
annot be administered intravenously due to their toxicities.
he interesting double mechanism of action of these compounds
rompts us to synthesize analogs of imiquimod. Based on this
nowledge, a new series of compounds has been synthesized,
he imidazo[1,2-a]quinoxalines, in order to evaluate its potential
nticancer properties, particularly in the treatment of melanoma
nd T lymphomas (Deleuze-Masquéfa et al., 2009a; Moarbess et
l., 2008a). Among the synthesized compounds, two of them,
APB0203 and EAPB0503, have the highest in vitro cytotoxic activ-
ty on melanoma (Deleuze-Masquéfa et al., 2009a; Moarbess et al.,
008a). Moreover, EAPB0203 at the dose of 20mg/kg by intraperi-
oneal route was more potent than fotemustine in xenografted
ude mice (Moarbess et al., 2008a). EAPB0203 also had promis-
ng cytotoxic activity on T lymphomas (Moarbess et al., 2008b).
ecently a liquid chromatography–mass spectrometry (LC–MS)
ethod has been developed to quantify EAPB0503 and its main
etabolite in human and rat plasma (Khier et al., 2009). Itwas used
o carry out a pharmacokinetic study in rat after administration of
his compound intravenously.
Theaimof thepresentpaperwas: (i) todevelopaLC–MSmethod
o quantify EAPB0203 and its main metabolite, EAPB0202, in rat
lasma; (ii) to determine pharmacokinetic parameters of these two
ompounds in rat after intravenous and intraperitoneal adminis-
rations; (iii) to estimate the sub-acute toxicity of EAPB0203 in rat
fter repeated intravenous administrations, once a day for 5 con-
ecutive days; and (iv) to evaluate the in vivo activity of EAPB0203
n xenografted nude mice at a lower dose (5mg/kg) in order to
stablish dose–response curve.
. Materials and methods
.1. Chemistry
EAPB0203 (N-methyl-1-(2-phenethyl)imidazo[1,2-a]quino-
alin-4-amine; molecular weight, 302; logP, 4.91; pKa,
.61), EAPB0202 (1-(2-phenethyl)imidazo[1,2-a]quinoxalin-
-amine; molecular weight, 288; logP, 4.97; pKa, 5.13) and
he internal standard (IS, EAPB0603, 1-(3-hydroxyphenyl)-N-
ethylimidazo[1,2-a]quinoxalin-4-amine; molecular weight,
90) used for method validation were synthesized according to
previously reported method from our group (Moarbess et al.,
008a; Deleuze-Masquéfa et al., 2009a, patent no. FR 2921927;
atent N◦ WO 2009043934). Brieﬂy, they were synthesized in
ood yields via a bimolecular condensation of 2-imidazole car-
oxylic acid, followed by a coupling with ortho-ﬂuoroaniline
nd subsequent substitution on the imidazole ring by Suzuki
ross-Coupling reaction using microwave assistance. The purity
f these standards was evaluated by elemental analysis, liquid
hromatography–mass spectrometry (LC–MS) and NMR. They
ere stored at 20 ◦C protected from light.
.2. Chemicals and reagents
All reagents were of analytical grade. Puriﬁed water (Milli-
puriﬁcation system, Millipore, Bedford, MA, USA), triﬂuo-
oacetic acid (TFA, Sigma, St. Louis, MO, USA), acetonitrile and
ichloromethane (Carlo Erba, Val de Reuil, France), ammonium
ormate (Fluka, Vandoeuvre, France), formic acid (Prolabo, Paris,
rance) and Oasis HLB cartridges (30mg sorbent, Waters, SaintPlease cite this article in press as: Khier, S., et al., Pharmacology of EAPB02
activity on melanoma. Eur. J. Pharm. Sci. (2009), doi:10.1016/j.ejps.2009.10
uentin, France) were used. Drug-free rat plasma provided from
harles River (L’Arbresle Cedex, France). Ammonium formate
uffer was prepared by mixing ammonium formate and water to
concentration of 2mM; the pH was adjusted to pH 3 with formic
cid. Stock solutions of EAPB0203, EAPB0202 and IS (40mg/L)
t
c
w
Q PRESS
ceutical Sciences xxx (2009) xxx–xxx
ere prepared in a mixture of acetonitrile–water–formic acid
49.5:49.5:1, v/v/v). These solutions were further diluted extem-
oraneously with the same mixture as appropriate to prepare
orking solutions (EAPB0203 and EAPB0202: 0.125–25mg/L; IS:
.6 and 8mg/L). These stock solutions were stored at +4 ◦C for 1
onth.
.3. LC–MS analysis
LC separation andMSdetectionwereperformedusing aHewlett
ackard Agilent 1100 quadrupolemass spectrometerworkingwith
n electrospray ionization source (ESI) (Agilent Technologies, Les
lis, France). The LC–MS conditions were close to those previously
ublished for two other compounds of the same chemical series
Khier et al., 2009). The chromatographic separation was achieved
n a C8 Zorbax eclipse XDB analytical column (150mm×4.6mm,
m, Agilent Technologies). The optimum mobile phase consisted
f, acetonitrile as solvent A and 2mM ammonium formate as
uffer B. The gradient elution was employed according to the
ollowing linear programme: time zero, 30% solvent A; 9min,
00% solvent A; 10min, 100% solvent A; 11min, 30% solvent A;
nd 14min, 30% solvent A. The ﬂow rate was 0.8mL/min and
he injection volume was 10L; the column was maintained at
0 ◦C and the autosampler temperature was 4 ◦C. The data acqui-
ition was under the control of HPChem Software (version 08.04,
gilent Technologies). Themass spectrometerwas operated inpos-
tive ion mode. Heated N2 gas (350 ◦C and 10L/min) was used
o evaporate solvent from the electrospray chamber and com-
ressed N2 gas (35psi) was used for nebulisation. Voltages were
et at +3.0 kV for the capillary and +0.5 kV for the skimmer lens.
he sampling cone voltages were set at 100V for EAPB0203 and
S, and at 80V for EAPB0202. For quantitative measurement of
APB0203 and EAPB0202, selective ion monitoring (SIM) was
mployed.
.4. Quantitation of EAPB0203 and EAPB0202 in rat plasma
.4.1. Sample preparation
A sample pre-treatment procedure close to that previously
escribed to analyse other compounds of the same chemical
eries, in rat and human plasma (Khier et al., 2009), was used
ith success to quantify these two new compounds. Brieﬂy, rat
lasma samples were pretreated to remove proteins. For this rea-
on, 0.5mL of water containing 10mL/L TFA was added to 0.5mL
f plasma samples (calibrators, QC or unknown samples) con-
aining the internal standard solution (20L, 1.6mg/L for low
alibration curves, 8mg/L for high calibration curves). After cen-
rifugation (4 ◦C) for 10min at 4000× g, the supernatant was
ransferred onto an Oasis HLB cartridge preconditioned with 1mL
f methanol and 1mL of water. The cartridge was then washed
ith 1mL of water and the analytes were eluted with 2mL of
ichloromethane. The eluates were evaporated to dryness under
itrogen at 40 ◦C. The residue was reconstituted with 100L of
mixture containing acetonitrile–water–formic acid (49.5:49.5:1,
/v/v).
.4.2. Calibration curves and QC samples
To 0.5mL of blank rat plasma, 20L of working solutions of the03, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral
.006
he 5–300g/L (low calibration curves), and 100–1000g/L (high
alibration curves) ranges.
Six levels of QC samples (15, 75, 200, 300, 500 and 750g/L)
ere prepared by adding to 0.5mL of drug-free matrix 20L of the
C working solutions.
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.4.3. Method validation
To link peak area ratios and theoretical concentrations of each
nalyte, two models were tested: (i) least-squares linear regres-
ion analysis and (ii) quadratic relationship. The resulting equation
arameters were used to calculate “back-calculated” concentra-
ions for the calibrators, which were then statistically evaluated
Bressolle et al., 1996). Between-day accuracy and precision of
he method were studied by analyzing QC samples (7–14 repli-
ates per QC) against a calibration curve and were expressed as
ercentage recovery and relative standard deviation (R.S.D.) of
eplicate measurements, respectively. In order to test whether it
as possible to apply the described method to samples whose rat
lasma concentrations were higher than the last calibration point,
QC sample containing 1600g/L of EAPB0203 and 1920g/L
f EAPB0202 was prepared, diluted 5-fold with blank drug-free
at plasma and analyzed 6 times against a calibration curve. The
bsolute extraction efﬁciencies for EAPB0203 and EAPB0202 were
etermined based on the comparison of the peak areas of extracted
C samples with those obtained by direct injections of the same
mount of both compounds (n=3 per concentration) dissolved in
cetonitrile–water–formic acid (49.5:49.5:1, v/v/v). The extraction
ecovery of the internal standard was also calculated. The lower
imit of quantitation (LLOQ) was deﬁned as the lowest drug con-
entration that could be determined with a precision <20% and a
ecovery of 80–120%.
The matrix effect was studied at the concentrations of QC sam-
les (prepared in six different pools of rat plasma in triplicate) and
as measured by referring the post-extracted spiked sample to
he unextracted samples (Viswanathan et al., 2007). To evaluate
ssay speciﬁcity drug-free plasma samples from six different pools
ere extracted without IS and analyzed for endogenous co-eluting
nterferences.
.4.4. Stability assays
For the stability study in rat plasma, drug-free control plasma
ampleswere spikedwithEAPB0203 andEAPB0202 at the concen-
rations of QC samples and analyzed against a calibration curve: (i)
mmediately, (ii) after storageat20and4 ◦C for4h, (iii) after storage
t −80 ◦C for 1 month, and (iv) after three freeze–thaw cycles. Each
etermination was performed in triplicate. The potential inﬂuence
f the evaporating step was also tested. Run-time stability at 4 ◦C
or 48h of processed samples in the autosampler was determined
or each calibrator.
.5. In vitro cytotoxic activity study
Experiments were conducted with two human melanoma can-
er cell lines: A375 and M4Be. These cell lines were obtained from
merican Type Culture Collection (Rockville, MD, USA). Cells were
aintained in RPMI-1640 (A375) or DMEM (M4Be)medium (Gibco
aboratories, France) supplemented with 10% heat-inactivated
56 ◦C) foetal bovine serum (FBS) (Polylabo, Paris, France), 2mM
-glutamine, 100 IU/mL penicillin G sodium, 100g/mL strep-
omycin sulphate, and 0.25g/mL amphotericin B. Cells were
ultured at 37 ◦C under 95% relative humidity in an atmosphere
ontaining 5% carbon dioxide in air. Only exponentially growing
iable cells were used for the study. The doubling times of A375
nd M4Be, in our experimental conditions, were approximately
8–20h. The day of experiment, cells were harvested with 0.02%
rypsin, 0.05% EDTA (Gibco Laboratories, France) for 5min at 37 ◦C,Please cite this article in press as: Khier, S., et al., Pharmacology of EAPB02
activity on melanoma. Eur. J. Pharm. Sci. (2009), doi:10.1016/j.ejps.2009.10
ounted and resuspended. Then, 200L of cell suspension (i.e.,
000 cells/well) were seeded with a multichannel pipette into the
ndividual wells of a 96-well tissue culture plate with lid (TPP,
rasadingen, Switzerland), and allowed to attach overnight. After
0–24h incubation, the medium was aspirated carefully from the
s
(
c
d
p PRESS
ceutical Sciences xxx (2009) xxx–xxx 3
lates using a sterile Pasteur pipette, and cells were exposed (in
riplicate) (i) to vehicle controls (1% DMSO/culture medium (v/v)
nd culturemediumalone), (ii) fotemustine and imiquimod at con-
entrations of 10−4 to 10−10 M, diluted in the culture medium, and
iii)EAPB0203 andEAPB0202 (10−4 to 10−10 M)dissolved in amix-
ure 1% DMSO/culture medium (v/v). After 96h of incubation, the
upernatant of each well was aspirated and 10L of MTT solution
5mg/mL in phosphate-buffer saline pH 7.3) was added to each
ell. The plates were incubated for 4h at 37 ◦C. Thereafter, the
upernatant was carefully aspirated, and 100L of a mixture of
sopropyl alcohol and 1M hydrochloric acid (96/4, v/v) was added
o each well. After 10min shaking, the optical density was mea-
ured at 570nm in amicroculture plate reader (DynatechMR5000,
rance). Each experiment was performed 3 times. Cell survival was
xpressed as percent of vehicle control. The IC50 values deﬁned
s the concentrations of drugs which produced 50% cell growth
nhibition, 50% reduction of absorbance, were estimated from the
igmoidal dose–response curves.
.6. In vivo studies
This research adhered to the “Principles of Laboratory Animal
are” (NIH publication #85-23, revised 1985). The animal studies
ere approved by the local Animal Use Committee.
.6.1. Pharmacokinetics
Sprague–Dawley rat were randomly distributed in two exper-
ment groups. In the ﬁrst group, rats received EAPB0203
ntravenously at the dose of 2.5mg/kg into the penis vein; in the
econd group, rats received EAPB0203 by intraperitoneal route at
he dose of 2.5mg/kg. Doses were chosen according to the 50%
ethal dose after intravenous administration (14.7mg/kg). Blood
amples (one sample per rat) were obtained at the following times
3 animals per time-point): 5, 10, 30min, and 1, 2, 4, 8, 12, 24 and
6h after drug administration. Blood samples were collected in
eparinized polypropylene tubes (0.1mL lithium heparinate per
ube) after sacriﬁce of the animal by section of the carotid artery,
hen immediately placed on ice. Two minutes prior to sampling,
nimals were anaesthetized with sevoﬂuran. Blood samples were
entrifuged (4000× g) at 4 ◦C for 10min. The plasmawas separated
hen immediately stored at −80 ◦C until assay. Pharmacokinetic
arameters (CL (total clearance); Vd (steady-state volume of dis-
ribution); AUC (area under curve) and terminal half-life) were
alculated by non-compartmental analysis from the average con-
entration values at each time point using the Pk-ﬁt software
Farenc et al., 2000; RDPP, 1999). When the concentrations were
elow thequantiﬁcation level, themeanvalueswereobtained from
everal values at, or above, the LLOQ with the other values taken as
ero.
.6.2. Sub-acute toxicity in rat
Rats were randomly distributed in three experiment groups:
i) in the ﬁrst group, 5 rats received intravenous administrations
f EAPB0203 (5mg/kg dissolved in 100L DMSO) into the tail
ein, once a day for 5 consecutive days; (ii) in the second group,
rats received the vehicle (100L DMSO) once a day for 5 consec-
tive days; and in the third group, 3 rats were untreated (control
roup). All rats were examined at least twice a day so as to record
ny signs of ill-health or behavior changes. The bodyweight was
ontrolled daily as well as the quantity of food and tap water con-03, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral
.006
umed. To evaluate possible bone narrow toxicity, blood samples
0.5mL, collected in EDTA polypropylene tubes) were drawn by
ardiac puncture just prior to drug administration, then 4 and 7
ays after the beginning of treatment. The following hematological
arameters, platelet count, red blood cells count, white blood cells
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ount, hemoglobin and hematocrit, were determined. After 5 days
f treatment, animals were euthanized, and a gross necropsy was
erformed. Brain, heart, liver, lung, kidney, and intestinewereﬁxed
n 10% buffered formalin, embedded in parafﬁn-wax, sectioned,
tained with hematoxylin-eosin then evaluated microscopically.
.6.3. Cytotoxic activity in xenografted mouse
We have previously shown that EAPB0203 (20mg/kg i.p., twice
week (monday and thursday) for 3 weeks followed by a second
ycle after awash-outof 15days), had signiﬁcanthigher anti-tumor
ctivity in human melanoma (M4Be) xenografted nude mice than
otemustine (weekly i.p. administration of 20mg/kg for 3 weeks
ollowedbyasecondcycleafter awash-outof15days) (Moarbesset
l., 2008a). In this paper, the in vivo cytotoxic activity of EAPB0203
as studied at a lowest dose and dose–response curves are pre-
ented. Tumor cells (3× 106) were inoculated subcutaneously into
he ﬂank area of female Swiss Nude mice as previously described
Moarbess et al., 2008a). Tumor growth was monitored twice a
eek. At a tumor size of ∼0.7 cm3 (i.e., 2 weeks after the graft),
thymic mice were randomly distributed into three experiment
roups (6 mice per group): (i) the vehicle control group (weekly
.p. administration of DMSO/intralipid (50:50, v/v) for 3 weeks),
ii) the EAPB0203 group (weekly i.p. administration of 5mg/kg
or 3 weeks), and (iii) the fotemustine group (weekly i.p. admin-
stration of 5mg/kg for 3 weeks). Only one cycle of treatment was
erformed. EAPB0203 being poorly soluble in water, it was dis-
olved in a mixture intralipid/DMSO (50:50, v/v). Fotemustine wasPlease cite this article in press as: Khier, S., et al., Pharmacology of EAPB02
activity on melanoma. Eur. J. Pharm. Sci. (2009), doi:10.1016/j.ejps.2009.10
issolved in 0.9% glucose. Animalswere euthanizedwith CO2 when
he tumor size reached2 cm3. A one-wayANOVA for repeatedmea-
urements was performed to compare (i) the variations in tumor
olume between the three treatment groups (control, fotemustine
nd EAPB0203), a simple contrast test was used to compare 2-by-2
3
n
r
Fig. 1. Typical chromatograms of drug-free rat plasma spiked with PRESS
ceutical Sciences xxx (2009) xxx–xxx
ach group; and (ii) the efﬁcacy of EAPB0203 treatment according
o the administered doses (5 and 20mg/kg). This analysis was per-
ormed using the PK-ﬁt software (Farenc et al., 2000; RDPP, 1999).
robability values of less than 0.05 were considered statistically
igniﬁcant.
. Results
.1. Quantitation of EAPB0203 and EAPB0202 in rat plasma
.1.1. Mass spectra and chromatography
EAPB0203 and EAPB0202 were evidenced by the protonated
olecules, [M+H]+, at m/z 303 and 289, respectively. The internal
tandard was characterized by the protonated molecule [M+H]+
t m/z 291. Representative chromatograms of a prespiked (5g/L)
lasma extracted sample are presented in Fig. 1. The retention
imes of EAPB0203, EAPB0202 and internal standard were 8.2, 7.3
nd 5.6min, respectively. Based on the distribution of the residuals
i.e., difference between nominal and back-calculated concentra-
ions), on the mean relative predictor error calculated from the
esiduals (not statistically different fromzero) andonprecision and
ccuracy values on the analysis of QC samples, quadratic calibra-
ioncurvesgave thebestﬁt for theconcentration/detector response
elationship for both EAPB0203 and EAPB0202. R.S.D. values on
he slope, b, were <23.5%.Mean back-calculated concentrations are
resented in Table 1. These results conﬁrmed the robustness and
eliability of the developed method.03, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral
.006
.1.2. Validation
The analysis of the analyte free samples (six different lots) did
ot show any interference from endogenous components at the
etention times of the three analytes assuring good selectivity.
EAPB0203 and EAPB0202 at the lower limit of quantitation.
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Table 1
Relative standard deviations and recoveries calculated from back calculated con-
centrations, from calibration curves performed in rat plasma.
Nominal concentrations (g/L) R.S.D., % (recovery, %)
EAPB0203, n=14 EAPB0202 n=7
Low calibration curves
5 11.8 (98) 9.70 (102)
7.5 7.41 (102) 9.01 (101)
10 4.39 (106) 9.04 (95.2)
20 4.03 (100) 5.35 (95)
50 8.34 (98) 6.99 (104)
100 6.47 (98) 5.50 (97)
300 0.97 (100) 0.27 (100)
High calibration curves
100 4.40 (93) 7.80 (99)
150 4.68 (102) 4.20 (104)
400 3.77 (104) 7.43 (98)
600 2.98 (96) 7.57 (106)
n
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Table 3
IC50 values against A375 and M4Be human melanoma cancer cell lines.
Compounds Formula IC50 (M± SD)
A375 M4Be
EAPB0203 C19H18N4 1.57 ± 0.56 2.58 ± 0.40
EAPB0202 C18H16N4 2.35 ± 0.15 –
Imiquimod 70.3 ± 4.3 33.5 ± 7.7
Fotemustine 173 ± 24 326 ± 34
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were similar to those recorded in the control group. There were
no treatment-associated deaths. No noticeable alterations were
recorded in the hematological analyses. The microscopic exami-
nation of the organ samples taken did not reveal any alterations
related to the administration of the compound.800 6.78 (100) 4.08 (99)
1000 1.26 (100) 4.15 (101)
, number of replicates, R.S.D., relative standard deviation.
he matrix effect was measured by referring the post-extracted
piked samples to the unextracted samples. The results indicated
hat no signiﬁcant matrix effects were occurring; the mean matrix
actors ranged from 92.5% to 113% (R.S.D.s, 1.0–5.0%). Extraction
ields data calculated at concentrations of QC samples were 75%
or EAPB0203 (CV, 7.7%), 77% for EAPB0202 (CV, 12.7%) and 72.4%
or the internal standard (CV, 10.9%), conﬁrming the good efﬁ-
iency of the extraction procedure. The overall interday precision
nd accuracy data are presented in Table 2. They were satisfac-
ory, with mean accuracy values ranging from 92% to 108% and
he R.S.D.s were lower than 11.5%. Dilution has no inﬂuence on the
erformance of themethod. After a 5-fold dilution, precision on the
esultswere <8%. The corresponding accuracy valueswere 100% for
APB0203 and 90% for EAPB0202. The LLOQ was 5g/L.
.1.3. Stability essays
The stability of the stock solutions was at least 1 month at 4 ◦C.
Spiked plasma QC samples with EAPB0203 and EAPB0202,
tored at −80 ◦C, were analyzed and stability was demonstrated
or 1 month. After bench-top storage at room temperature and at
◦C for 4h, recoveries were >91%. Repeated freeze/thaw cycles did
ot affect the stability of EAPB0203 and EAPB0202. Reconstituted
xtracts in the acetonitrile–water–formic acid mixture were stable
n the autosampler for 48h at 4 ◦C.Please cite this article in press as: Khier, S., et al., Pharmacology of EAPB02
activity on melanoma. Eur. J. Pharm. Sci. (2009), doi:10.1016/j.ejps.2009.10
.2. In vitro cytotoxic activity
EAPB0203 produced signiﬁcant in vitro growth inhibition
gainst both A375 and M4Be cell lines. This compound was much
ore active than fotemustine and imiquimod used as references.
able 2
etween-day accuracy and precision of the method.
Nominal concentrations (g/L) Precision, % (accuracy, %)
EAPB0203, n=14 EAPB0202, n=7
Low calibration curves
15 6.13 (101) 8.89 (102)
75 7.54 (95) 6.63 (101)
200 10.6 (101) 9.10 (96)
High calibration curves
300 4.70 (108) 10.0 (100)
500 3.58 (103) 4.72 (93)
750 5.30 (97) 11.1 (92)
F
m
eC50, concentration of the compound producing 50% cell growth inhibition after 96h
f drug exposure, as determined by the MTT assay; SD, standard deviation.
ach experiment was run 3 times in triplicate.
esults are presented in Table 3. Concerning EAPB0202, this com-
ound was 1.5 times less active than the parent drug on A375 cell
ine. Fig. 2 presents the growth-inhibitory effects of EABP0203 and
APB0202, against A375 human melanoma cell line determined
y MTT assay. These curves show a very steep decrease in cell
roliferation.
.3. In vivo studies
.3.1. Pharmacokinetic proﬁles
Semilogarithmic plots of the mean (±SD) EAPB0203 and
APB0202 (active metabolite) plasma concentration–time proﬁles
re presented in Fig. 3. After intravenous administration, pharma-
okinetic parameterswere as follows: (i)EAPB0203: CL, 3.2 L/h/kg;
d, 11.1 L/kg; AUC, 0.78mgxh/L; and terminal half-life, 2.4 h; (ii)
APB0202: AUC, 0.029mgxh/L; and terminal half-life, 2.0 h. After
ntraperitoneal administration, rapid absorption occurred, phar-
acokinetic parameters were: (i) EAPB0203: AUC, 0.15mgxh/L;
nd terminalhalf-life, 1.5 h; (ii)EAPB0202: AUC, 0.032mgxh/L; and
erminal half-life, 0.91h. The absolute bioavailability of EAPB0203
y intraperitoneal route was 22.7%.
.3.2. Sub-acute toxicity
After repeated administrations, the treatment was well tol-
rated without weight loss or decrease in food and tap water
onsumed. The bodyweight increase and the food andwater intake03, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral
.006
ig. 2. EffectofEABP0203 () andEAPB0202 () on theproliferationofA375human
elanoma cell line using MTT viability assay. Data are the mean of 3 independent
xperiments carried out in triplicate. Error bars represent SD.
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big. 3. Plasma concentration time curves after single 2.5mg/kg intravenous (,
APB0203; ©, EAPB0202) and intraperitoneal (, EAPB0203; , EAPB0202) doses
f EAPB0203 to male rats (mean± SD; three rats per time point).
.3.3. In vivo cytotoxic activity
The treatments were well tolerated without apparent side
ffects or weight losses. As expected, M4Be xenografts grew pro-
ressively in the vehicle control mice. At the dose of 5mg/kg, the
ariations in tumor growth, according to the treatment group,
ave similar proﬁles than after the 20mg/kg dose (Moarbess et al.,
008a). Mice treated with EAPB0203 or fotemustine approached
signiﬁcant delay in tumor growth. However, lower signiﬁcant
ifferences between the two groups of treatment were observed
han after administration of 20mg/kg. A signiﬁcant difference onlyPlease cite this article in press as: Khier, S., et al., Pharmacology of EAPB02
activity on melanoma. Eur. J. Pharm. Sci. (2009), doi:10.1016/j.ejps.2009.10
ccurred by day 34.
The efﬁcacy of treatment is dose-related (Fig. 4A). In mice
eceiving EAPB0203, the decrease in tumor growth was signiﬁ-
antly higher, from day 18 (P=0.026) to day 46 (P≤0.005) after
he 20mg/kg dose than after administration of 5mg/kg. In animals
ig. 4. (A) Antitumoral effect curves of EAPB0203 at two dose levels 5mg/kg ()
nd 20mg/kg () in human melanoma (M4Be) xenografted nude mice. Data are the
ean of one experiment carried out on six mice per group. Error bars represent
D. (B) Survival time in human melanoma (M4Be) xenografted nude mice (n=6 per
roup): fotemustine (20mg/kg once a week for 3 weeks) (); EAPB0203 (20mg/kg
wice a week for 3 weeks) (); control ().
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reated by fotemustine, the difference between the two doses was
ess pronounced (days 24 (P=0.017), 27 (P=0.019), 31 (P=0.0046)
nd 34 (P=0.0052)).
. Discussion
Since several years, we develop imidazoquinoxaline drugs
ith interesting anti-tumoral activity against both lymphomas
Moarbess et al., 2008b) and melanoma (Deleuze-Masquéfa et al.,
009a; Moarbess et al., 2008a). We have recently shown that
midazo[1,2-a]quinoxaline derivatives inhibit cyclic nucleotide
hosphodiesterase enzymes 4, resulting in increased intracellular
AMP level, and consequently CREB phosphorylation (Deleuze-
asquéfa et al., 2004), and that these compounds activate the
38 MAPK pathway, and inhibit the PI3K pathway (Morjaria
t al., 2006). The mechanism of action of EAPB0203 has been
tudied on T cell lymphomas and HTLV-I associated adult T-
ell leukemia/lymphoma (Moarbess et al., 2008b). This compound
xhibits inhibition of cell proliferation, G2/M cell cycle arrest, and
nduction of apoptosis in HTLV-I transformed and HTLV-I negative
alignant T cells while normal resting or activated T lymphocytes
re resistant. Furthermore, EAPB0203 almost completely inhib-
ted the growth of freshly isolated ATL cells at concentrations
f 1–10M. EAPB0203 treatment signiﬁcantly down-regulated
he anti-apoptotic proteins c-IAP-1 and Bcl-XL, and resulted in a
igniﬁcant loss of mitochondrial membrane potential, cytoplas-
ic release of cytochrome c, and caspase dependent apoptosis. In
ddition, in HTLV-I transformed cells only, EAPB0203 treatment
tabilized p21 and p53 proteins but had no effect on NF-B activa-
ion. However, the speciﬁc cellular target of EAPB0203 remains to
e identiﬁed.
The method developed herein to quantify EAPB0203 and
APB0202 in rat plasma has been fully validated in terms of selec-
ivity, accuracy, precision, stability and sensitivity. The lower limit
f quantitation was estimated as 5g/L for both compounds. We
erformed two different calibration curves to cover the possible
ider range of concentrations tominimise thenumber of unknown
amples to dilute. The sample preparation involved protein pre-
ipitation followed by solid-phase extraction, the most efﬁcient
rocedure to minimize matrix effects (Marchi et al., 2007; Xu et
l., 2005). This method was found suitable for the analysis of blood
amples drawn during a pharmacokinetic study carried out in rat.
After intravenous administration, systemic clearance of
APB0203 (3.2 L/h/kg) was notably less than the typical cardiac
lasma output in rat, but higher than the average liver and kidney
lasmaﬂows (Davies andMorris, 1993). The volume of distribution
11.1 L/kg) was well in excess of the total body water volume,
uggesting extensive tissue distribution. Biotransformation of
APB0203 involves demethylation leading to an active metabolite,
APB0202. For this metabolite, a lower terminal half-life was
ound after intraperitoneal administration than after intravenous
dministrations (0.91h versus 2.0h). After intraperitoneal admin-
stration, the limit of the assay sensitivity being reached at 4.0h
fter dosing instead of 8h after intravenous administration (Fig. 3),
his resulted in an underestimation of the half-life of the terminal
art of the curve.
After intraperitoneal administration the absolute bioavailability
as 22.7%.
On A375 melanoma cancer cell line, EAPB0203 (IC50 =1.57M)
ad an in vitro activity 110 times higher than fotemus-03, a novel imidazo[1,2-a]quinoxaline derivative with anti-tumoral
.006
ine (IC50 =173M) and 45 times higher than imiquimod
IC50 =70M). Its metabolite, EAPB0202, had about 65% of the
ctivity of the parent drug. On M4Be melanoma cancer cell line,
APB0203was also more potent than fotemustine and imiquimod.
APB0203 also presents interesting in vitro anti-tumoral activi-
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ies on other cancer cell lines (Moarbess et al., 2008a). In mouse
enograft model, EAPB0203 is more potent than fotemustine both
fter administration of 5 and 20mg/kg intraperitoneally (Moarbess
t al., 2008a). At the dose of 20mg/kg, the effect of EAPB0203
n mice survival time is presented in Fig. 4B. The survival time
as increased up to approximately 4 weeks compared to control
ice and up to 2 weeks compared to mice treated by fotemustine.
he results of this study demonstrate the relationship between the
ose of EAPB0203 and its effects on tumor growth (Fig. 4A). Taking
nto account the bioavailability of EAPB0203 after intraperitoneal
dministration in rat of 22.7%, this compound had remarkable in
ivo activity at doses equivalent to 1 and4mg/kg (i.e., 0.227×dose)
ntering the systemic circulation.
. Conclusion
EAPB0203 is a promising candidate in the treatment of
elanoma and T lymphomas. This compound exhibits cytotoxi-
ity in tumor models superior to that of fotemustine, both in vitro
nd in vivo. Due to the double mechanism of action of these com-
ounds: (i) direct by induction of apoptosis (conﬁrmed on T cell
ymphomas, in vitro) and (ii) indirect by production of cytokines,
his new series of anticancer agents appears of utmost interest and
eserves attention for continuation of preclinical studies. Promis-
ng efﬁcacy, tolerance and pharmacokinetic data in mice and rat
ncourage the development towards patient beneﬁt.
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